Compare Fiverr International Ltd (FVRR) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs Travere Therapeutics Inc. Common Stock — how do they compare? Fiverr International Ltd trades at $8.56 (market cap $309.18M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 15.8× Fiverr International Ltd's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Fiverr International Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fiverr International Ltd for 62 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FVRR | TVTX | |
|---|---|---|
Market Cap | $309.18M | $4.88B |
Volume | 481,205 | 1,668,577 |
Sector | Media | Health |
52-Week High | $23.60 | $67.52 |
52-Week Low | $8.47 | $26.79 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $61.56M | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $8.55, down 0.81% with bearish technical signals despite attractive valuation metrics including a P/E of 10.62 and P/S of 0.75. Recent Q2 2026 earnings missed expectations with revenue declining 10% year-over-year as AI disruption pressures freelance demand. The company maintains strong gross margins of 82% but faces headwinds from accelerating AI adoption compressing lower-value freelance work.
While valuation appears compelling with consensus price target of $10.50 representing 23% upside, near-term risks from AI disruption and recent earnings misses warrant caution. Analyst sentiment leans neutral with 76% hold ratings, reflecting uncertainty around growth trajectory amid structural industry shifts. Cash flow trends show volatility with negative net cash flow projected for 2026.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
